Inside Precision Medicine December 18, 2025
Uniting sequencing with cutting-edge clinical genomics analyses for early detection could shift care upstream, enabling earlier treatment and prevention
For Premal Shah, PhD, CEO of clinical whole-genome analysis company MyOme, the idea that he might be at high risk for a heart attack is not abstract—it is personal history.
“My dad had a heart attack at 50 and is alive, my uncle dropped dead at 50, and my cousin dropped dead at 50,” Shah told Inside Precision Medicine. “I’m 49. It’s real. It’s absolutely real.”
Even in Shah’s case, traditional clinical risk calculators painted a reassuring picture. Standard cardiovascular assessments, based on cholesterol levels, blood pressure, and age, suggested little cause for alarm.
“If you plug in my LDL, HDL,...
Today's Sponsors
Today's Sponsor